drugset
drugset / Trial / NCT05208853

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

NCT05208853 ↗

Phase 0 Unknown 9 enrolled Zhejiang University Shanghai First Song Therapeutics Co., Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open label, single dose study of anti CD30 CAR-T cells injection in treatment of patients with relapsed/refractory CD30+ lymphoma.

Timeline

Start
2022-02-10
Primary completion
2022-02-10
Completion
2022-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti-CD30 CAR T cells Cell therapy 1.5e+07 cells Intravenous
Subject Anti-CD30 CAR T cells Cell therapy 1.5e+08 cells Intravenous
Subject Anti-CD30 CAR T cells Cell therapy 5e+08 cells Intravenous

Indications

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma Hodgkins lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma peripheral T-cell lymphoma, not otherwise specified primary mediastinal large B-cell lymphoma